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Smac/Diabloermeabilization (MMP) is commonly regarded as the “point-of-no-return” in the
cascade of events that delineate the intrinsic pathway of apoptosis. MMP leads to the functional impairment
of mitochondria and to the release into the cytosol of toxic proteins that are normally conﬁned within the
mitochondrial intermembrane space. These include direct activators of caspases and caspase-independent
effectors of the cell death program. MMP has been implicated in a plethora of pathophysiological settings. In
particular, MMP contributes to both the immediate and delayed phases of cell loss that follow acute neuronal
injury by ischemia/reperfusion or trauma. Although preventing MMP a priori would be the most desirable
therapeutic choice, prophylactic interventions are rarely (if ever) achievable in the treatment of stroke and
trauma patients. Conversely, interventions that block the post-mitochondrial phase of apoptosis (if
administered within the ﬁrst few hours after the accident) hold great promises for the development of
novel neuroprotective strategies. In animal models of acute neuronal injury, the inhibition of caspases,
apoptosis-inducing factor (AIF) and other apoptotic effectors can confer signiﬁcant neuroprotection. Our
review recapitulates the results of these studies and proposes novel strategies of inhibiting post-
mitochondrial apoptosis in neurons.
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Apoptosis constitutes a highly regulated mechanism for the
removal of supernumerary, ectopic, old, damaged or mutated cells,
that can be executed by two distinct (yet partially overlapping)
molecular mechanisms [1]. On one hand, the extrinsic apoptotic
pathway mediates cell death in response to extracellular stimuli. This
can occur either through the ligand-induced activation of death
receptors at the plasma membrane [2,3], or as a result of signaling
cascades that emanate from dependency receptors in the absence of
their ligands [4]. On the other hand, intrinsic apoptosis is regulated by
mitochondria, which integrate lethal and pro-survival signals, to
eventually reach a decision on the cell's fate [5]. If the death sentence
is pronounced, mitochondrial membrane permeabilization (MMP)
takes place and cells trespass the frontier between life and death, the
“point-of-no-return” in the cascade of events that delineates this
lethal routine (which is also known as “mitochondrial apoptosis”)
[6,7]. Irrespective of the initiating signals, the extrinsic and the
intrinsic pathway converge on the massive activation of catabolic
enzymes (including a class of cysteine proteases known as caspases,
non-caspase proteases, lipases and endonucleases), which account for
the execution of apoptosis and (at least partially) for its morphological
appearance [1,8,9].
MMP has a number of consequences that contribute to cell death,
which include (but are not limited to): (1) loss of the mitochondrial
transmembrane potential (ΔΨm), in turn leading to the arrest of
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particular of ATP synthesis through the F0 F1-ATP synthase); (2)
uncoupling of the respiratory chain, which results in the over-
production of reactive oxygen species (ROS) and further ampliﬁes
the functional impairment of mitochondria; and (3) release into the
cytosol of proteins that in healthy cells are secured within the
mitochondrial intermembrane space (IMS), where they serve vital
functions [10–12]. These comprehend enzymes with an intrinsic
catabolic activity (e.g., apoptosis-inducing factor, i.e., AIF, endonu-
clease G, i.e., EndoG, several pro-caspases) [13,14], direct activators of
caspases (e.g., cytochrome c, i.e., Cyt c) [15,16], as well as proteins that
block and/or degrade endogenous inhibitors of caspases, thereby
indirectly favoring the execution of cell death (e.g., Smac/DIABLO,
Omi/HtrA2) [17,18] (Table 1). Thus, on one hand MMP leads to a
bioenergetic, biosynthetic and redox crisis that coincides with the
complete collapse of cellular metabolism, and, on the other hand, it
triggers multiple mechanisms that actively degrade the cellular
content. Ultimately, MMP results in cell death, which may manifest
with the classical morphological hallmarks of apoptosis (e.g.,
chromatin condensation, karyorrhexis, pyknosis, shedding of apopto-
tic bodies) or by exhibiting a necrotic and/or an autophagic
phenotype. In this regard, it should be noted that the inhibition of
caspases often shifts the appearance of cell death from full-blown
pictures of apoptosis to a non-apoptotic morphology, and concomi-
tantly delays (but rarely, if ever, prevents) its ultimate occurrence
[1,8,9].
At present, two major models have been put forward to describe
the mechanisms through which mitochondrial membranes become
permeabilized (Fig. 1). In some settings, MMP results from protein-
permeable pores formed across the outer mitochondrial membrane
(OM) by proapoptotic members of the Bcl-2 protein family (e.g., Bak,
Bax) [19,20]. Such pores are responsible for the early release of IMS
proteins, followed by blockade of the respiratory chain (due to the loss
of IMS-soluble components like Cyt c), ROS overgeneration, ΔΨmTable 1
Consequences of mitochondrial membrane permeabilization (MMP) [12]
Primary event Outcomes — observations
Bioenergetic failure
Ca2+ release Favors PTPC opening in yet unaffected mitochondria.
Favors the activation of Ca2+-dependent catabolic enzymes (e.g
ΔΨm dissipation Blockade of ATP synthesis and of other mitochondrial metaboli
ROS overproduction Uncoupling of the respiratory chain, in turn favoring MPT.
ROS favor MPT also in yet unaffected mitochondria.
Morphological, structural and ultrastructural modiﬁcations
Fragmentation of the
mitochondrial network
Underscores the implication of the mitochondrial fusion/ﬁssion
Mitophagy Permeabilized mitochondria are selectively sent to autophagic r
Swelling Results from the unregulated entry of solutes and water in the
Release into the cytosol of IMS proteins (examples)
AIF Together with CypA, translocates to the nucleus where it media
Cyt c Interacts in a dATP-dependent fashion with Apaf-1 to assemble
of pro-caspase-9.
De-inhibits IP3Rs, thereby favoring the increase of cytosolic Ca2
Its loss results in the uncoupling of the respiratory chain, in tur
mitochondria.
EndoG Translocates to the nucleus and mediates caspase-independent
Heat-shock proteins (e.g.,
Hsp10, Hsp60)
Their depletion from the IMS favors the disruption of the struct
Consistent with their role of chaperones, they accelerate caspas
Omi/HtrA2 Binds to and hence sequestrates IAPs, in turn favoring caspase a
Cleaves IAPs and other substrates, thereby promoting caspase-d
Pro-caspases (e.g., -3, -9) Kept in an inactive state by S-nitrosylation in the IMS, upon rel
processing. Pro-caspase-9 can be directly activated by redox str
Smac/DIABLO Binds to and hence sequestrates IAPs, in turn favoring the activ
Abbreviations: AIF, apoptosis-inducting factor; Apaf-1, apoptotic peptidase activating fact
transmembrane potential; EndoG, endonuclease G; Hsp, heat-shock protein; IAP, inhibitor
trisphosphate receptor; MPT, mitochondrial permeability transition; Omi/HtrA2, Omi stress-
transition pore complex; ROS, reactive oxygen species; Smac/DIABLO, second direct activatdissipation, and functional breakdown of mitochondria [21,22] (Fig.
1A). In response to a plethora of apoptotic stimuli, Bax and Bak, which
in healthy cells are in a latent state, undergo conformational changes
allowing for homo- and/or hetero-oligomerization. This structural
reorganization often involves a direct physical interaction with
another class of Bcl-2 family members that function as intracellular
sensors of stress, namely BH3-only proteins (e.g., Bid, Bad, Bim)
[23–25]. In this context, a third group of proteins from the Bcl-2 family
(e.g., Bcl-2, Bcl-XL) exerts antiapoptotic functions by sequestering
their proapoptotic counterparts into inactive complexes [26], as well
as via extramitochondrial mechanisms (for instance by modulating
Ca2+ ﬂuxes at the endoplasmic reticulum) [27].
In other instances, MMP is triggered by an abrupt increase in the
permeability of the mitochondrial inner membrane (IM) to low-
molecular weight solutes, which is known as mitochondrial perme-
ability transition (MPT). MPT derives from the opening of the so-
called permeability transition pore complex (PTPC), a supramolecular
entity assembled at the junctions between IM and OM. MPT provokes
an osmotic imbalance that leads to a net inﬂux of water into the
mitochondrial matrix, swelling of the matrix and eventually physical
rupture of the OM (Fig. 1B) [28,29]. Although the precise molecular
composition of the PTPC still remains a matter of debate, some
consensus has emerged on its minimal scaffold structure, which
includes the voltage-dependent anion channel (VDAC) in the OM, the
adenine nucleotide translocase (ANT) in the IM, and cyclophilin D
(CypD) in the mitochondrial matrix [30,31]. In addition, the activity of
the PTPC (which responds to proapoptotic signals such as Ca2+
overload and oxidative stress) is regulated by the association with
several interacting partners, including the peripheral-type benzodia-
zepine receptor (PBR) [32], the mitochondrial creatine kinase (CK)
[33], multiple isoforms of hexokinase (HK) [34,35], as well as pro- and
antiapoptotic Bcl-2-like proteins [36].
Beside its role in numerous physiological settings (e.g., embryonic
and post-embryonic development, homeostasis of highly proliferatingRef.
[167]
., calpains). [167]
sms. [28, 29]
[168]
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machinery in cell death pathways. [169,170]
emoval. [171,172]
mitochondrial matrix that follows MPT. [12]
tes chromatin condensation and DNA degradation. [14,126]
the apoptosome, a molecular platform for the activation [15,16]
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or 1; Ca2+, calcium; CypA, cyclophilin A; Cyt c, cytochrome c; ΔΨm, mitochondrial
of apoptosis protein; IMS, mitochondrial intermembrane space; IP3R, inositol (1,4,5)
regulated endoprotease/high temperature requirement protein A 2; PTPC, permeability
or of caspases/direct IAP-binding protein with a low pI.
Fig. 1. Models of mitochondrial membrane permeabilization (MMP). (A) In some instances, MMP originates at the mitochondrial outer membrane (OM), due to the pore-forming
activity of proapoptotic proteins from the Bcl-2 family (e.g., Bak, Bax). In physiological conditions, Bak and Bax exist in an inactive conformation, loosely associatedwith the OM and in
the cytosol, respectively. Under proapoptotic stimulation, they undergo a conformational change that allows them to fully insert into the OM and to form homo-/heteromeric pores
though which mitochondrial intermembrane space (IMS) proteins are released. These include soluble components of the respiratory chain (RC) such as cytochrome c. The release of
IMS proteins favors mitochondrial uncoupling, overgeneration of reactive-oxygen species (ROS) and dissipation of the mitochondrial transmembrane potential (ΔΨm), which
altogether account for the functional impairment of mitochondria. (B) In other cell death scenarios, MMP is started at the inner mitochondrial membrane (IM), following the
activation of the permeability transition pore complex (PTPC). In healthy cells, the PTPC ensures the exchange of metabolites between the mitochondrial matrix and the cytosol. In
response to some proapoptotic triggers (e.g., Ca2+ overload, oxidative stress), the PTPC opens, thereby allowing for the unregulated entry of solutes and water into the mitochondrial
matrix. This abrupt increase in the permeability of the IM – also known as mitochondrial permeability transition (MPT) – results in the osmotic swelling of the mitochondrial matrix,
and eventually in the osmotic pressure-driven rupture of the OM.
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human diseases. Thus, while disabled apoptosis is associated with
both the development and the limited therapeutic response of cancer,
disproportionate cell loss contributes to acute and chronic degen-
erative pathologies in a variety of organs, including liver, heart, kidney
and the central nervous system (CNS) [12]. In all these pathological
settings, cell death does not occur exclusively with an apoptotic
morphology but may also manifest with a necrotic and/or autophagic
appearance [12,37,38].
As compared to other cells, neurons have a very high energetic
demand. This is a direct consequence of the molecular processes
underlying their excitability (all of which require large amounts of
ATP), which include the maintenance of a precise ionic homeostasis,
axonal and dendritic transports, and the release/reuptake of neuro-
transmitters at the synaptic cleft. Moreover, since neurons cannot
switch to anaerobic glycolysis when oxidative phosphorylation is
limited, they are even more dependent than other cell types on
mitochondrial metabolism. For these reasons, neurons are especially
sensitive to glucose and oxygen deprivation as they occur after
ischemic and traumatic insult of the CNS [39,40].
During acute neuronal damage, necrosis is themost prominent cell
death phenotype in the core of lesions, whereas apoptosis predomi-
nates in adjacent zones, at the boundary between the lesion and
healthy tissue (also known as the “penumbra”). Since the necrotic
core is presumably damaged beyond any possibility of recovery,
therapeutic interventions most frequently aim at inhibiting apoptosis,
and therefore at reducing neuronal loss in the penumbra [41]. In this
context, the inhibition of MMP confers neuroprotective effects in vivo,
in numerous animal models of CNS ischemia and trauma (Table 2)
[42].
In the best case scenario, patients affected by stroke or trauma are
treated within dozens of minutes, but usually this occurs only within
hours, that is after MMP has been initiated. Since ischemic and
traumatic injuries of the CNS are responsible for the protracted
disability and death of millions of individuals throughout the world,and since current treatments are mainly intended to reduce cellular
inﬁltrate, limit edema and favor the resolution of inﬂammation (and
hence in a way represent symptomatic therapies), novel neuropro-
tective strategies that actively prevent the acute loss of neurons are
urgently awaited. Such interventions should target the post-mito-
chondrial effectors of apoptosis, allowing to block the cascade of
events that lead to neuronal cell death when MMP has already
occurred. Nonetheless, even the possibility to target post-MMP events
would not abolish the need to treat patients affected by stroke or CNS
trauma with maximal urgency. First, the early removal of the cause of
injury (for instance the dissolution of an arterial clot) is known to limit
the area of neuronal damage, by reducing the duration of the insult. In
addition, the efﬁcacy of post-mitochondrial apoptosis inhibitorswould
be greatly improved if they were administered during the ﬁrst phases
of cell death, before catabolic reactions have been ignited. Finally, in
case of an early intervention (and in particular before all affected
neurons have undergone MMP), combination therapies that associate
MMP blockers with inhibitors of post-mitochondrial apoptosis might
confer enhanced neuroprotection, by preventing unwarranted cell
death both upstream and downstream of mitochondria.
2. Keeping Pandora's box closed: inhibition of mitochondrial
membrane permeabilization (MMP)
The inhibition of MMP by pharmacological and/or genetic means
has been associated with signiﬁcant neuroprotective effects in vivo, in
multiple animalmodels of stroke or traumatic injury of the spinal cord
(Table 2). In this context, the cascade of events that leads to cell death
is interrupted well before the functional impairment of mitochondria
and themassive activation of catabolic reactions, which represents the
most efﬁcient strategy to prevent neuronal loss. In spite of the fact that
this approach is not realistic in the clinical setting, several studies have
corroborated its (at least) theoretical validity [40, 42].
Pharmacological inhibitors of the pore-forming activity of Bax (but
not of its conformational activation nor of its translocation to
Table 2
Examples of neuroprotection conferred in vivo by mitochondrial membrane permeabilization (MMP) inhibitors
Target Strategy/Model Observations Ref.
Pre-mitochondrial signaling (Initiation phase)
JNK jnk3 gene knockout Following H/I, jnk3−/− mice exhibited less Casp-3 activation and reduced tissue loss in the cerebral cortex,
hippocampus, striatum and thalamus as compared to WT animals.
[177]
Systemic administration of a JNK-speciﬁc peptide
inhibitor (Tat-JBD)
Upon I/R, Tat-JBD-treated rats exhibited lower Bax mitochondrial translocation, Cyt c release, Casp-3
activation, PARP-1 cleavage and TUNEL reactivity than control animals.
[70]
Systemic administration of a small JNK-speciﬁc
inhibitor (SP600125)
Upon focal I/R, treated mice displayed reduced mitochondrial translocation of Bax and Bim, IMS proteins
release, Casp-3 and -9 activation, and infarct volume as compared to control animals.
[69]
p53 p53 gene knockout Following kainate-induced excitotoxicity, neuronal damage was limited to the dorsal hippocampus in p53−/
−mice, while it also involved the amygdala, piriform and cerebral cortex, caudate-putamen and thalamus in
WT animals.
[67]
Systemic administration of a small p53-speciﬁc
inhibitor (piﬁthrin-α)
Piﬁthrin-treated mice exhibited increased resistance of cortical and striatal neurons to tFCI and of
hippocampal neurons to excitotoxic damage as compared to control animals.
[66]
SOD1 Whole-body overexpression Upon tFCI, SOD1-overexpressing mice had lower oxidative injury, reduced release of IMS proteins from
mitochondria, and enhanced XIAP/Casp-9 interaction than WT animals.
[158,166]
Mitochondrial events (Decision/integration phase)
ANT Oral administration of HIV-1 PIs (nelﬁnavir and
ritonavir)
PIs prevented AIF and Cyt c release from mitochondria, Casp-9 activation and photoreceptor cell loss in a
murine model of RD. Upon MCAO, PI-treated mice showed lower TUNEL reactivity and infarct volumes than
control animals.
[108,134]
Bad bad gene knockout Following H/I, bad−/−mice exhibited reduced Casp-3 activation and GFAP positivity in their hippocampi as
compared to WT animals, which correlated with reduced tissue loss.
[54]
Bax bax gene knockout bax−/− mice subjected to CCI exhibited fewer TUNEL+ cells in the hippocampus than their WT littermates
(but performed worse in behavioral tests, independently of the traumatic injury).
[50,51]
Intraperitoneal injection of small BCIs Upon tGCI, hippocampi from BCI-treated gerbils exhibited lower Cyt c release and more limited tissue
damage than hippocampi from saline-treated animals.
[43]
Intravenous administration of TUDCA before or
after the injury
Following tFCI and ICH, TUDCA-treated rats displayed reduced TUNEL positivity, mitochondrial swelling,
Casp activation and lesion volume than control animals, which correlated with an improvement in
neurobehavioral deﬁcits.
[44,45]
Bcl-2 Neuron-speciﬁc overexpression In mice overexpressing Bcl-2 under the control of a neuron-speciﬁc promoter, MCAO-induced brain
infarction volume was reduced by approximately 50% as compared to WT animals.
[47]
Bcl-XL Neuron-speciﬁc overexpression Mice overexpressing Bcl-XL under the control of a cortex-speciﬁc promoter exhibited a 20% reduction in
MCAO-induced brain infarction volume as compared to their WT littermates.
[49]
Bid bid gene knockout After MCAO or mild focal ischemia, bid−/−mice displayed lower Cyt c release and infarct volumes than their
WT counterparts.
[52,53]
Bim bim gene knockout Upon H/I, bim−/−mice displayed reduced Casp-3 activation and GFAP positivity in their brains as compared
to WT animals, which correlated with reduced hippocampal tissue loss.
[54]
CypD Intraperitoneal injection of a non-
immunosuppressive CsA analogue (MeVal-CsA)
Upon MCAO, MeVal-CsA-treated rats exhibited lower cortical and striatal infarct size than vehicle-treated
animals.
[56]
Intravenous administration of CsA after the injury High CsA concentrations, the presence of an intracerebral needle lesion or the intracarotid infusion of
mannitol allowed CsA to cross the BBB and reduced tFCI-induced infarct size in rats.
[57]
ppif gene knockout Following MCAO, ppif−/−mice displayed a dramatic reduction in brain infarct size as compared to their WT
littermates.
[61]
Systemic administration of CsA before the injury In response to tFCI, CsA-treated rats showed decreased ischemic brain edema and infarct size as compared to
control animals.
[55]
Abbreviations: AIF, apoptosis-inducing factor; ANT, adenine nucleotide translocase; BBB, blood–brain barrier; BCIs, Bax channel activity inhibitors; BH, Bcl-2 homology; Casp, caspase;
CCI, controlled cortical impact; CsA, cyclosporine A; CypD, cyclophilin D, GFAP, glial ﬁbrillary acidic protein; H/I, hypoxia/ischemia; HIV-1, human immunodeﬁciency virus 1; IAP,
inhibitor of apoptosis protein; ICH, intracerebral hemorrhage; IMS, mitochondrial intermembrane space; I/R, ischemia/reperfusion; JBD, JNK binding domain of JIP-1; JIP-1, JNK-
interacting protein 1; JNK, c-Jun N-terminal kinase; MCAO, middle cerebral artery occlusion; PARP-1, poly(ADP-ribose) polymerase 1; ppif, peptidyl–prolyl cis–trans isomerase f; PI,
protease inhibitors; RD, retinal detachment; SOD1, copper/zinc-superoxide dismutase; tFCI, transient focal cerebral ischemia; tGCI, transient global cerebral ischemia; Tat, Tat
peptide from HIV-1; TUDCA, tauroursodeoxycholic acid; TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling; WT, wild type; XIAP, X-linked IAP.
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animal model of global brain ischemia [43]. Also, the endogenous bile
acid tauroursodeoxycholic acid (TUDCA) protected rats against
neurological injury after transient focal cerebral ischemia (tFCI) [44]
and intracerebral hemorrhage [45], presumably by inhibiting the
association of Bax with mitochondria [46]. The implication of Bcl-
2-like proteins in the pathogenesis of CNS ischemia and trauma has
been substantiated by the use of genetically engineered animals to
achievewhole-bodyor tissue-speciﬁc changes in the expression of Bcl-
2 family members. As an example, mice overexpressing antiapoptotic
members of the Bcl-2 family such as Bcl-2 itself [47,48] or Bcl-XL [49]
displayed reduced tissue damage after permanent focal ischemia.
Similarly, bax−/− mice had signiﬁcantly less hippocampal tissue loss
upon neonatal hypoxia/ischemia (H/I, a model of cerebral palsy) [50]
or controlled cortical impact (CCI, a model of traumatic brain injury)
[51] than bax+/− and bax+/+ animals, and adult mice devoid of the
BH3-only protein Bid exhibited decreased Cyt c release from
mitochondria and reduced infarct volumes – as compared to their
wild type (WT) littermates – after transient focal ischemia [52,53].However, as opposite to bim−/− and bad−/− animals (which displayed
decreasedparenchymal loss as compared to control littermates), bid−/−
micewere not protected fromneonatal H/I [54]. This suggests that BH3-
only proteins may be selectively implicated in distinct scenarios of
ischemic injury.
More than 15 years ago, the immunosuppressant cyclosporine A
(CsA), which binds to CypD and hence inhibits PTPC opening, has been
shown to confer neuroprotection against focal ischemia, when
administered for several days prior to injury [55]. Similar effects
were observed with the CsA derivative MeVal-CsA, which blocks MPT
but does not bind to calcineurin and therefore lack immunosuppres-
sant activities [56]. This proved that the neuroprotective effects of CsA
are (at least partially) due to MPT inhibition, in spite of the fact that
other immunosuppressants that do not bind to CypD (e.g., FK-506)
may also protect from focal and permanent ischemia [57–59]. More
recently, the crucial role of PTPC-dependent MPT in ischemic injury
has been unquestionably corroborated by studies in ppif−/− mice
(which lack the expression of CypD) [60]. CypD-deﬁcient mice
displayed a dramatic reduction in brain infarct size following acute
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mouse embryonic ﬁbroblasts (MEFs) and mitochondria isolated from
ppif−/− mice were relevantly resistant to triggers of necrosis
(including Ca2+ overload and oxidative stress) but normally respon-
sive to apoptotic stimuli, CypD deﬁciency was suggested to confer
neuroprotection in vivo by regulating necrotic, rather than apoptotic,
cell death [62]. Interestingly, a role for other components of the PTPC
(and in particular for ANT and VDAC) in CNS ischemia and trauma has
not (yet) been unquestionably demonstrated [12], in line with the fact
that no sign of cell death resistance could be detected in vitro for
ant−/− [63] and vdac−/− [64,65] cells.
Although this is beyond the scope of the present review, it should
be noted that signiﬁcant levels of neuroprotection have been achieved
in vivo by inhibiting MMP further upstream, at the initiation phase
that precedes mitochondrial commitment. Just to mention some
examples, neuroprotective effects against different types of CNS injury
(including ischemia, trauma and excitotoxicity) have been recorded
upon pharmacological [66] and genetic [67] inhibition of the tumor
suppressor protein p53, in mice lacking the neuronal nitric oxide
synthase (NOS) gene [68], as well as upon systemic administration of
small molecules [69] or peptides [70] designed to block the c-Jun
N-terminal kinase (JNK) signaling pathway.
3. When Pandora's box has opened: inhibition of
post-mitochondrial apoptotic effectors
When MMP has already occurred, as in the majority of affected
neurons in stroke and/or trauma patients, therapeutic interventions
to limit neuronal loss should be directed at inhibiting the post-
mitochondrial events that lead to cell death. Hereafter, we will
summarize the results of studies performed in animal models of acute
neuronal injury (Table 3).
3.1. The caspase cascade
Upon MMP, several IMS proteins that directly promote the
activation of the caspase cascade are released into the cytosol (Fig. 2)
[71]. These include: Cyt c, which together with the cytosolic protein
apoptotic peptidase activating factor 1 (Apaf-1) and dATP forms the
so-called “apoptosome”, a molecular platform that recruits and
allosterically activates pro-caspase-9 [15,16]; multiple pro-caspases
that act as apoptotic executioners downstream of mitochondria and/
or that are implicated in feedforward circuitries to amplify proapop-
totic signals [72], such as pro-caspase-2 [73], -3 [74], -8 [75] and -9
[73,76]; as well as chaperones of the heat-shock protein (Hsp) family
(e.g., Hsp10, Hsp60), which may modulate the activity of the apop-
tosome [77].
Caspase-3 is classically considered as the prototype of executioner
caspases and is the most abundant caspase in the brain [78–80]. Most
casp-3−/− mice die perinatally and manifest a hyperplasic, disorga-
nized brain [81], which demonstrates that caspase-3 is crucial during
the embryonic development of the nervous system. Acute inhibition of
caspases via quite unspeciﬁc pharmacological agents (such as the
pan-caspase inhibitor Z-Val-Ala-Asp(OMe)-ﬂuoromethylketone, i.e.,
Z-VAD-fmk) administered after the insult has been reported to confer
neuroprotection in adult models of ischemia [82–85] and traumatic
CNS injury [86–88]. In other rat models of transient focal or global
ischemia, however, the activation of caspases could not be demon-
strated, and pan-caspase inhibitors such as Z-VAD-fmk or (relatively)
caspase-3-speciﬁc blockers like Z-Asp(OMe)-Glu(OMe)-Val-Asp
(OMe)-ﬂuoromethylketone (Z-DEVD-fmk) failed to provide any neu-
roprotective effect [89,90]. This argues against a generalized implica-
tion of the caspase cascade in ischemic brain injury, and suggests that
(at least in some scenarios), caspase-independent mechanisms may
prevail. Moreover, a selective caspase-3/-7 inhibitor (M826) adminis-
tered immediately after the insult [91] aswell asmore unspeciﬁc agents(such as boc-Asp(OMe)-fmk, i.e., boc-D-fmk) [92,93] have been
demonstrated to confer impressive protection during neonatal H/I
injury [91,92] and after traumatic brain injury [93]. Thus, the
involvement of caspases during ischemic CNS injury may not only
vary in different pathological settings, but also during aging (from
neonatal to adult life), in line with age-associated changes in the
expression and activity levels of multiple apoptotic regulators (and in
particular of caspases) [94,95]. Although the vast majority of casp-3−/−
mice die perinatally due to extensive brain hyperplasia and impaired
CNS development [81], some animals exhibit milder defects and reach
adulthood, during which they are more resistant to ischemic injuries
than their WT littermates [96]. Moreover, strain-speciﬁc brain
phenotypes resulting from caspase-3 deﬁciency have been reported
[97], presumably due to the “rescue” by other caspases, and in par-
ticular by caspase-7 [98]. Interestingly, it has been recently suggested
that the long-term inhibition of caspase-3 during development (as it
occurs in casp-3−/− and casp-3+/− mice) leads to the upregulation of
caspase-independent cell death routines, thereby increasing the
vulnerability of the developing brain to neonatal H/I injury [99].
The neurodevelopmental phenotype of casp-3−/− mice [81],
which include marked ventricular zone expansion, exencephaly and
ectopic neuronal structures, is recapitulated in both apaf-1−/− [100]
and casp-9−/− animals [97,101], suggesting that these proteins ensure
the correct development of the CNS by participating in a common cell
death pathway. The knockout of the other component of the
apoptosome, i.e., Cyt c, results in an even more severe phenotype
(cyc1−/− embryos die in utero by midgestation) [102], due to its
essential function as an electron shuttle in the respiratory chain [15].
This has greatly limited the possibility to analyze in vivo, in adult
animals, the role of Cyt c, Apaf-1 and caspase-9 during ischemic and/
or traumatic brain injuries. Recently, mice that express a mutant Cyt c
(the KA mutation), which retains normal electron transfer functions
but fails to activate the apoptosome, have been generated [103]. Most
KA/KA mice exhibit embryonic or perinatal lethality due to extensive
CNS disarrangement, which demonstrates that the lethal (but not the
vital) functions of Cyt c are implicated in CNS development [103].
Moreover, the forebrain overgrowth (fog) mutation, which was
described as a spontaneous recessive mutation mapping to mouse
chromosome 10, coincides with an hypomorphic Apaf-1 defect that
leads to reduced levels of normal Apaf-1 mRNA [104]. Although fog/
fog mice are characterized by forebrain abnormalities, facial defor-
mities and spina biﬁda, they survive into adulthood, thereby
representing valuable models to study Apaf-1 deﬁciency in vivo [104].
Nevertheless, for the abovementioned reasons, few studies have
evaluated the role of the constituents of the apoptosome during acute
neuronal injury, mostly based on (unspeciﬁc) pharmacological agents.
Selective inhibition of caspase-9 after tFCI (as obtained by intraven-
tricular injection of a speciﬁc inhibitor 15 min after the insult) was
reported to reduce total infarction volume and to improve the
neurological score in a rat model of ischemia/reperfusion (I/R) injury
[105]. Similarly, repeated intraocular injection of speciﬁc caspase-9
inhibitors was shown to prevent the death of retinal ganglion cells
upon optic nerve transection (a model of traumatic injury) in rats
[106]. At present, other pharmacological inhibitors of the apoptosome
are not yet available for in vivo use. Interestingly, small molecules that
bind to and inhibit Apaf-1 have been recently identiﬁed [107], but
their activity in animal models of acute neuronal injuries remains to
be established. A recent study indicates that Apaf-1 is required
(together with AIF, see below) for the death of photoreceptor cells that
occurs in a murine model of retinal detachment [108]. In this context,
the fog/fog genotype resulted in decreased activation of caspases and
conferred signiﬁcant neuroprotection (as compared to WT animals).
Given the destructive consequences of massive caspase activation,
it is not surprising that cells have evolved multiple caspase-
suppressivemechanisms, including the family of inhibitor of apoptosis
proteins (IAPs) [109]. Most IAPs share a baculoviral IAP repeat (BIR)
Table 3
Examples of neuroprotection conferred in vivo by inhibitors of post-mitochondrial effectors of apoptosis
Target Strategy/Model Observations Ref.
Caspase-dependent cell death mechanisms
Apaf-1 fog/fog mice (homozygous hypomorphic Apaf-1
mutation)
Upon RD, retinae from fog/fog mice exhibited lower Casp-activation, TUNEL positivity, photo-
receptor cell loss and overall histological derangement than their counterparts from WT animals.
[108]
Caspases Intracerebroventricular injections of boc-D-fmk after the
insult
24 h after TBI, boc-D-fmk-treated rats displayed decreased Cyt c release, Casp-3 activation, TUNEL
reactivity and cortical tissue loss as compared to control animals, but this did not resulted in long-
term neuroprotection and improvement of motor function.
[93]
Intracerebroventricular and systemic injections of boc-D-
fmk after the insult
In rats subjected to neonatal H/I, boc-D-fmk strikingly reduced Casp-3 activation, TUNEL positivity
and striatal, cortical and hippocampal tissue loss, as compared to a control peptide.
[92]
Intracerebroventricular injection of Z-VAD-fmk before
and after the insult
Z-VAD-fmk-treated mice subjected to MCAO or excitotoxic brain damage exhibited limited
increase in tissue IL-1β levels and improved behavioral deﬁcits as compared to untreated animals.
[82]
UponMCAO, Z-VAD-fmk-treated mice displayed lower TUNEL staining in the striatum than control
animals, which correlated with decreased infarct size and reduced neurologic deﬁcits.
[83,85]
Infarction volumes following cold injury-brain trauma were signiﬁcantly reduced in Z-VAD-fmk-
treated mice as compared to vehicle-treated animals.
[86]
Intrastriatal injection of Z-VAD-fmk after the insult Z-VAD-fmk protected mice against malonate-induced striatal histotoxic hypoxic lesions, as
assessed by reduced lesion volume as compared to untreated animals.
[84]
Local application of Z-VAD-fmk-soaked sponges on
contused spinal cords
In mice, post-SCI Casp-3 activation, TUNEL reactivity, lesion size and neurologic deﬁcits were
signiﬁcantly ameliorated by the local application of Z-VAD-fmk, as compared to vehicle control.
[87]
Systemic (?) administration of Z-VAD-fmk Upon SCI, Z-VAD-fmk-treated mice exhibited reduced TUNEL positivity, tissue injury and
inﬂammatory reactions than untreated animals, which correlated with improved recovery of limb
function.
[88]
Casp-3 casp-3 gene knockout After MCAO, casp-3−/− mice exhibited decreased TUNEL positivity and cortical infarct volume, as
compared to their WT littermates.
[96]
Intracerebroventricular injection of M826 after the insult Upon H/I, M826-treated mice displayed reduced Casp-3 activation, cleavage of Casp-3 substrates,
DNA fragmentation and brain tissue loss, as compared to untreated control animals.
[91]
Intracerebroventricular injection of Z-DVED-fmk before
and after the insult
Following MCAO, the striatum of Z-DVED-fmk-treated mice exhibited reduced TUNEL positivity as
compared to control animals, which was accompanied by decreased infarct size and minor
neurologic deﬁcits.
[83,85]
Casp-9 Intracerebroventricular injection of Z-LEHD-fmk after the
insult
Z-LEHD-fmk-treated rats (as compared to vehicle-treated animals) subjected to MCAO exhibited a
decrease in total infarct volume and improved neurological outcomes.
[105]
Intraocular injection of Casp-9-speciﬁc inhibitors In rats, casp-9 inhibition prevented the death of axotomized RGCs that follows optical nerve
transection (a model of TBI).
[106]
NAIP Intrahippocampal injection of an adenoviral
overexpression vector before the insult
In rats subjected to tFCI, adenovirus-mediated overexpression of NAIP (but not of β-gal) reduced
DNA fragmentation and hippocampal neuron loss.
[114]
Systemic administration of the bacterial alkaloid K252a
before the insult
Upon tFCI, K252a-treated rats exhibited reduced DNA fragmentation and hippocampal neuron loss,
as compared to vehicle-treated animals.
[114]
p35 Adenoviral delivery of a transient overexpression vector
after the insult
In adult rats, local administration of an adenoviral vector for the overexpression of p35 (but not of
β-gal) at the nerve stump reduced the death of RGCs following axotomy.
[111]
Oligodendrocyte-speciﬁc overexpression Upon SCI, transgenic mice demonstrated a lesser extent of demyelination and cell death, as well as
an improved recovery of hindlimb motor function, as compared to control animals.
[118]
XIAP Adenoviral delivery of a transient overexpression vector
after the insult
In adult rats, local administration of a XIAP-overexpressing (but not of a β-gal-overexpressing)
adenoviral vector at the nerve stump inhibited the death of RGCs following axotomy.
[111]
Adenoviral delivery of a transient overexpression vector
before the insult
Transgenic mice undergoing tFCI displayed reduced Casp-3 activation, TUNEL positivity and
hippocampal neurodegeneration as compared to their WT littermates.
[113]
Intraperitoneal injection of PTD-BIR3-RING peptide
before and after the insult
Rats treated with PTD-BIR3-RING and subjected to MCAO were characterized by lower Casp-3
activation and TUNEL reactivity than untreated rats, which correlated with improved NSS.
[116]
Neuron-speciﬁc overexpression Mice subjected to MCAO exhibited lowered TUNEL labeling, decrease in protein synthesis and
Casp-3 activation in neurons as compared to WT animals.
[178]
Whole-body overexpression As opposed toWTanimals, transgenic mice subjected to H/I almost failed to activate casp-9 and -3,
which correlated with reduced tissue loss in multiple brain regions.
[112]
Caspase-independent cell death mechanisms
AIF Male Hq/Y mice (hemizygous hypomorphic AIFHq
mutation)
In a model of kainic acid-induced seizure, Hq mice exhibited lower levels of neuronal loss and
hippocampal damage than WT animals.
[129]
After MCAO, Hq mice exhibited decreased infarct volumes and dramatically reduced cell death in
the ischemic penumbra, as compared to their WT littermates subjected to the same insult.
[130]
Following RD, retinae from Hq/Ymice displayed lower Casp-activation, TUNEL positivity, photo-
receptor cell loss and overall histological derangement than their counterparts fromWT animals.
[108,128]
Male (Hq/Y) and female (Hq/Hq) newborn mice (hemi-
and homozygous AIFHq mutation, respectively)
Upon H/I, Hq mice showed infarct volumes reduced by approximately 50% as compared to their
WT littermates. These neuroprotective effects were further enhanced by the administration of a
broad-spectrum caspase inhibitor or antioxidants.
[131,132]
CypA cypA gene knockout cypA−/− and cypA+/− mice subjected to H/I failed to exhibit the nuclear translocation of AIF that
was observed in WT mice, which correlated with a reduction in infarct size of approximately 50%.
[123]
Modulators of both caspase-dependent and -independent cell death
Hsp70 Brain-speciﬁc overexpression of WT and mutant Hsp70 Following MCAO, mice overexpressing in the brain WT Hsp70 (as well as ATPase-deﬁcient Hsp70
mutants) showed lower levels of nuclear AIF than control animals, had signiﬁcantly smaller
infarcts and higher neurological scores.
[142]
Whole-body overexpression Upon H/I, mice overexpressing rat Hsp70 showed limited release of Cyt c and increased AIF/Hsp70
binding, which correlated with signiﬁcant neuroprotection, as compared to WT animals.
[140]
Abbreviations: AIF, apoptosis-inducting factor; Apaf-1, apoptotic peptidase activating factor 1; β-gal, β-galactoside; boc-D-fmk, boc-Asp(OMe)-fmk; Casp, caspase; CypA, cyclophilin
A; Cyt c, cytochrome c; BIR3, baculoviral IAP repeat 3 domain; fog, facial overgrowth; H/I, hypoxia/ischemia; Hq, Harlequin; Hsp70, heat-shock 70 kDa protein; IL-1β, interleukin 1;
MCAO, middle cerebral artery occlusion; NAIP, neuronal apoptosis inhibitory protein; NSS, neurological severity score; PTD, protein transduction domain; RD; retinal detachment
RGCs, retinal ganglion cells; RING, real interesting new gene; SCI, spinal cord injury; TBI, traumatic brain injury; tFCI, transient focal cerebral ischemia; TUNEL, terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling; WT, wild type; Z-DEVD-fmk, Z-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-ﬂuoromethylketone; Z-LEDH-fmk, Z-
Leu-Glu(OMe)-His-Asp(OMe)-ﬂuoromethylketone; Z-VAD-fmk, Z-Val-Ala-Asp(OMe)-ﬂuoromethylketone.
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Fig. 2. Inhibition of post-mitochondrial effectors of apoptosis for neuroprotection. Mitochondrial membrane permeabilization (MMP) leads to the release into the cytosol of a
plethora of proteins that are normally found within the mitochondrial intermembrane space. Upon MMP, several among these factors contribute to cell death. Pharmacological and
genetic approaches that target post-mitochondrial cell death effectors have been shown to confer neuroprotective effects in various animal models of acute neuronal damage,
including (but not limited to) models of focal and global brain ischemia, neonatal hypoxia/ischemia and traumatic injury of the spinal cord. Please, refer to the main text for further
details. AIF, apoptosis-inducing factor; Apaf-1, apoptotic peptidase activating factor 1; boc-D-fmk, boc-Asp(OMe)-fmk; Casp, caspase; CypA, cyclophilin A; Cyt c, cytochrome c;
EndoG, endonuclease G; Hsp70, heat-shock 70 kDa protein; IAPs, inhibitor of apoptosis proteins; Omi/HtrA2, Omi stress-regulated endoprotease/high temperature requirement
protein A 2; Smac/DIABLO, second direct activator of caspases/direct IAP-binding protein with a low pI; Z-DEVD-fmk, Z-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-ﬂuoromethylketone;
Z-LEDH-fmk, Z-Leu-Glu(OMe)-His-Asp(OMe)-ﬂuoromethylketone; Z-VAD-fmk, Z-Val-Ala-Asp(OMe)-ﬂuoromethylketone.
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they interact with and therefore prevent the activation of caspases
[109,110]. In multiple models of acute neuronal injury, IAPs have been
shown to mediate neuroprotective effects. Thus, transgenic over-
expression of the X-linked IAP (XIAP) in the brain conferred
neuroprotection against axotomy [111], neonatal H/I [112] and tFCI
in adult mice [113]. Similarly, enhanced expression of the neuronal
apoptosis inhibitory protein (NAIP) reduced tFCI-induced damage in
the rat brain [114]. Interestingly, tFCI increases the ubiquitination of
XIAP in rat brain, which in turn might modulate its subcellular
distribution and activity [115]. More recently, the intraperitoneal
injection of a chimeric peptide made by the BIR3-RING domains of
XIAP fused to the protein transduction domain (PTD) of antennapedia
homeodomain (Antp HD) has been shown to efﬁciently transduce
hippocampal neurons, thereby exerting neuroprotective effects
against tFCI in rats [116]. Viral proteins that inhibit caspases have
also been used to develop neuroprotective strategies.[117] For
instance, the broad spectrum caspase inhibitor p35 has been shown
to prevent the death of retinal ganglion cells (RGCs) in rats subjected
to optic nerve transection [111], as well as to reduce demyelination
and motor function loss in a murine model of spinal cord injury (SCI)
[118]. These few examples underscore the notion that the IAP family as
well as exogenous caspase inhibitors might represent promising
targets to control the caspase cascade for neuroprotection.3.2. Mitochondrial DNA-degrading enzymes
Apoptosis-inducing factor (AIF) is an IMS NADH oxidase with a
local redox activity that is required for the correct assembly and/or
function of the respiratory chain [14], as demonstrated by the fact that
AIF deﬁciency results in reduced oxidative phosphorylation and
lowered expression of complex I and III subunits, in vivo [119]. Mice
bearing the Harlequin (Hq) mutation express only 20% of the AIF
levels of theirWTcounterparts, due to a retroviral insertion in the ﬁrst
intron of the AIF gene. Although young Hqmice do not exhibit obvious
phenotypic alterations, adult animals develop ataxia, cerebellar
atrophia and blindness [120]. Muscle-speciﬁc knockout of AIF leads
to severe mitochondrial dysfunction, skeletal muscle atrophy and
dilated cardiomiopathy [121]. Moreover, muscle- and liver-speciﬁc AIF
ablation leads to a pattern of metabolic changes that counteract the
development of insulin resistance, diabetes and obesity [122]. Upon
MMP, AIF is released into the cytosol and translocates to the nucleus,
where it promotes (together with its obligate cofactor cyclophilin A,
i.e., CypA) chromatin condensation and DNA degradation[123,124]
independently of caspases [125,126]. Although the contribution of AIF
to cell death is highly variable according to the speciﬁc experimental
and/or pathophysiological setting [21], this caspase-independent
executioner has been repeatedly described as a major determinant
in the demise of neurons after acute injury [127,128].
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kainic acid-induced seizures [129] and MCAO [130] than their WT
littermates. Similarly, AIF deﬁciency has been shown to confer
neuroprotective effects following neonatal H/I [131,132] that could
be further enhanced by the administration of broad spectrum caspase
inhibitors or antioxidants [132]. In rodent models of retinal detach-
ment (obtained by the subretinal injection of sodium hyaluronate),
AIF is required for the death of photoreceptor cells [128,133]. In this
system, the hypomorphic AIFHq mutation (as well as the fog/fog
genotype, see above) provided signiﬁcant protection against photo-
receptor apoptosis [108]. Even more remarkable effects resulted from
the use of an antiapoptotic Bcl-2-derived BH4 peptide coupled to a
membrane-permeant sequence, as well as from the oral administra-
tion of the HIV protease inhibitors nelﬁnavir and ritonavir [108],
which are known to inhibit MMP at the mitochondrial level by
interacting with ANT [134]. In line with in vitro data suggesting that
AIF must interact with CypA to form a proapoptotic DNA degradation
complex [124], neurons from Hq mice subjected to H/I failed to
manifest the nuclear translocation of CypA that was observed in WT
neurons [123]. More importantly, the H/I-induced nuclear relocaliza-
tion of AIF was suppressed in cypA−/−mice, and this correlated with a
reduction in infarct volume by approximately 50% as compared to WT
animals [123].
Besides preventing the assembly of the apoptosome by binding to
Apaf-1 [135,136], the chaperon Hsp70 has been shown to sequester
AIF in the cytosol uponMMP, thereby interfering with its proapoptotic
potential [137]. Moreover, Hsp70 has been described to prevent the
mitochondrial release of AIF [138], thereby acting at two distinct levels
of the molecular pathway that activates AIF-dependent DNA degrada-
tion. Accordingly, hsp70−/− mice responded to an ischemic insult by
manifesting a greater infarction volume in the cortex thanWTanimals
[139]. Conversely, in a model of neonatal H/I, Hsp70 overexpression
limited the mitochondrio-nuclear translocation of AIF and provided
signiﬁcant neuroprotection [140]. While the interaction between
Hsp70 and Apaf-1 requires ATP and the ATP-binding domain (ABD) of
Hsp70, it is still unclear whether this domain is needed for the
cytosolic sequestration of AIF. Early works reported that a Hsp70
variant lacking ABD retains the ability to inhibit apoptosis in vitro, in
cell death models that are also affected by micro-injection of anti-AIF
antibodies as well as by its genetic ablation [141]. In a more recent
work also based on cultured cells, it has been shown that both the
ATPase and chaperon domains of Hsp70 are critical for impeding the
release of AIF from mitochondria, while only the former would be
required to sequester AIF in the cytosol and therefore prevent its
nuclear translocation [138]. Finally, in vivo data obtained in a rat
model of ischemic injury (which followed the brain-targeted
transfection of plasmids for overexpressing different mutants of
Hsp70) suggest that the C-terminal portion of Hsp70 is sufﬁcient for
neuroprotection, irrespective of the functionality as well as of the
presence of its N-terminal ATPase domain [142]. Taken together, these
experimental results provide a solid basis for the development of
neuroprotective strategies based on Hsp70-mediated inhibition of AIF.
Endonuclease G (EndoG) is an DNase encoded by the nuclear
genome that normally resides in the IMS [13]. Upon MMP, EndoG is
released into the cytosol and translocates to the nucleus, where it
cleaves chromatin DNA independently of caspases [143]. Although
early reports suggested that the endoG−/− genotype is incompatible
with life and results in embryonic lethality [144], it has been recently
demonstrated that this phenotype was due to the disruption of an
adjacent gene, and that endoG−/− mice can develop into adulthood
without obvious abnormalities [145]. EndoG nuclear translocation has
been detected in the brain of mice subjected to tFCI [146], as well as in
sensory cells of the inner ear upon noise trauma [147]. At present,
however, no studies have evaluated the response of EndoG-deﬁcient
animals to ischemic and traumatic brain injuries. Interestingly, assays
based on puriﬁed cellular components suggest that the DNase activityof EndoG could be suppressed by Hsp70, in an ATP-dependent manner
[148].
3.3. Other mitochondrial apoptotic effectors
The stress-regulated endoprotease Omi (also known as high
temperature requirement protein A 2, i.e., HtrA2) is a serine protease
that shows extensive homology to the Escherichia coli HtrA gene
products, which are essential for bacterial survival at high tempera-
tures [149]. Human Omi/HtrA2 has been implicated in both caspase-
dependent and caspase-independent cell death mechanisms that
originate from MMP, due to its ability to release caspases from IAP-
mediated inhibition [150,151] and to promote the cleavage of caspase-
unrelated substrates (e.g., cytoskeletal proteins) [152], respectively. In
particular, Omi/HtrA2 inhibition of IAPs relies both on their
sequestration [150] and on their proteolytic degradation [151].
However, mice in which the omi gene has been removed by
homologous recombination [153,154], as well as mnd2 mice (whose
phenotype results from a loss-of-function mutation in omi) [155],
exhibit early onset neurodegeneration with features of Parkinson
disease, as well as juvenile lethality. These observations suggest that
Omi/HtrA2 has a prominent role in cell survival, rather than in cell
death, at least in vivo [10,11]. Although the contribution of Omi/HtrA2
to chronic neurodegenerative disorders such as Parkinson disease has
been extensively explored [156,157], its implication in acute neuronal
injury is poorly characterized. Cytosolic translocation of Omi/HtrA2
and its enhanced interactionwith XIAP have been reported to occur in
vivo, in mice subjected to tFCI [158]. This could not be prevented by Z-
VAD-fmk administration, but was signiﬁcantly reduced in the brain of
mice overexpressing the copper/zinc-superoxide dismutase (SOD1),
pointing to a contribution of ROS (but not of caspases) to the
molecular pathways leading to ischemia-induced Omi/HtrA2 release.
Direct IAP-binding protein with a low pI (DIABLO, whose murine
ortholog is known as second mitochondria-derived activator of
caspase, i.e., Smac) closely resembles Omi/Htra2 in several aspects:
(i) it is a nuclear DNA-encoded factor that normally resides within the
IMS and is released into the cytosol following MMP [159,160]; (ii)
cytosolic Smac/DIABLO promotes cell death by sequestering IAPs,
thereby favoring caspase activation [18]; (iii) smac−/− mice are
viable, grow normally into adulthood and do not exhibit any
histological abnormalities [161]. At difference with Omi/HtrA2,
Smac/DIABLO does not display any proteolytic activity, and hence
inhibits IAPs merely by physical engagement [162]. tFCI has been
shown to promote the cytosolic translocation of Smac/DIABLO in both
rats [163] and mice [164,165], in the latter case though a pathway that
could be counteracted by SOD1 overexpression [166].
4. Concluding remarks
The observations discussed in this review underscore the notion
that, although blocking cell death at the MMP level would represent
the most efﬁcient strategy, the inhibition of post-mitochondrial
apoptotic executioners may also result in considerable neuroprotec-
tion (Fig. 2). This is of great importance in view of the fact that the
majority of stroke and trauma patients are treated hours after the
insult. At this stage, most (if not all) neurons in the affected region
either have already died or have undergone MMP. Thus, novel
therapeutic strategies are urgently awaited to block (or at least
inhibit) executioner mechanisms that are already in motion.
Thus far, results from in vivo studies based on animal models of
acute CNS injury (e.g., focal and global brain ischemia, neonatal H/I,
traumatic injury of the spinal cord) have lent strong support to the
hypothesis that blocking post-mitochondrial apoptotic mechanisms
would exert neuroprotective effects. Multiple lethal pathways are
activated upon MMP to execute cell death. Thus, as elegantly
demonstrated in murine models of neonatal H/I [132] or retinal
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therapies that inhibit more than a single cell death effector (e.g., the
caspase cascade and AIF). Moreover, the possibility to modulate the
activity of lethal proteins in an indirect fashion, by pharmacologically
activating their endogenous regulators, urgently awaits further
investigation. In particular, Hsp70, which has been shown to regulate
both caspase-dependent and -independent cell death by interacting
with Apaf-1 [135], AIF [137] and EndoG [148], may represent a
promising target for neuroprotection.
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